Skip to main content
SpringerLink
Log in

Objective Assessment of Clinical Disease Activity

  • Chapter
  • First Online:
Crohn's Disease and Ulcerative Colitis

Abstract

An objective assessment of disease activity is an important prerequisite to clinical trials establishing the efficacy of new drugs or treatment strategies. Furthermore, while new objectives are developed for the global management of inflammatory bowel disease, leading to new treatment strategies aiming at a tighter control of the disease, it becomes important to have available user-friendly tools adequate for disease activity quantification and helping the clinician in treatment decisions. In ulcerative colitis, clinical activity of the disease has been rather well correlated to endoscopic activity and a large number of indices including or not an endoscopic assessment have been developed for a specific use in clinical trials. The simpler amongst them, like the Mayo score are also adapted for routine practice. In Crohn’s disease, the Crohn’s disease activity index has almost been the unique index used in clinical trials for more than 30 years. However, due to its poor correlation to intestinal lesions assessed either by endoscopy or cross-sectional imaging it is now abandoned in pivotal clinical trial, being replaced by a combination of endoscopic assessment and patients reported symptoms. For everyday routine practice, a simple score mainly based on patient’s symptoms, like the Harvey Bradshaw index or close variants potentially recorded by the patient him/herself, seems appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis. 1966;11:847–57.

    Article  CAS  PubMed  Google Scholar 

  2. Seo M, Okada M, Maeda K, Oh K. Correlations between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol. 1998;93:2124–9.

    Article  CAS  PubMed  Google Scholar 

  3. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811–8.

    Article  CAS  PubMed  Google Scholar 

  5. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992;102:1647–53.

    Article  CAS  PubMed  Google Scholar 

  6. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–8.

    Article  PubMed  Google Scholar 

  7. Frøslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–22.

    Article  PubMed  Google Scholar 

  8. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246–56.

    Article  PubMed  Google Scholar 

  9. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.

    Article  PubMed  Google Scholar 

  10. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ. 1955;2:1041–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833–7.

    Article  CAS  PubMed  Google Scholar 

  12. Lichtiger S, Present DH. Preliminary report: cyclosporin treatment of severe active ulcerative colitis. Lancet. 1990;336:16–9.

    Article  CAS  PubMed  Google Scholar 

  13. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.

    Article  CAS  PubMed  Google Scholar 

  14. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology. 1987;92:1894–8.

    Article  CAS  PubMed  Google Scholar 

  15. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–6.

    CAS  PubMed  Google Scholar 

  16. Walmsley RS, Ayres RC, Pounder RE, Akkan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ. 1989;298:82–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g) and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398–407.

    CAS  PubMed  Google Scholar 

  19. Feagan BG, Greenberg GR, Wild G, Fedorak R, Pare P, McDonald JWD, et al. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N Engl J Med. 2005;352:2499–507.

    Article  CAS  PubMed  Google Scholar 

  20. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.

    Article  CAS  PubMed  Google Scholar 

  21. Seo M, Okada M, Yao T, Okabe N, Matake H, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparison between a new activity index and Truelove and Witts classification. Am J Gastroenterol. 1995;90:1759–63.

    CAS  PubMed  Google Scholar 

  22. Seo M, Okada M, Yao T, Matake H, Maeda K. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol. 2002;37:29–34.

    Article  PubMed  Google Scholar 

  23. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Grännö C, et al. Infliximab as a rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.

    Article  PubMed  Google Scholar 

  24. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis. 2012;6:991–1030.

    Article  PubMed  Google Scholar 

  25. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909–15.

    Article  CAS  PubMed  Google Scholar 

  26. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci. 1982;27:533–7.

    Article  CAS  PubMed  Google Scholar 

  27. Higgins PD, Schwartz M, Mapili J, Zimmerman EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005;100:355–61.

    Article  PubMed  Google Scholar 

  28. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet. 1980;1:514.

    Article  CAS  PubMed  Google Scholar 

  29. Higgins PDR, Schwartz M, Mapili J, Krokos I, Leung J, Zimmerman EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–85.

    Article  CAS  PubMed  Google Scholar 

  31. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994;106:1429–35.

    Article  CAS  PubMed  Google Scholar 

  32. Sandborn WJ, Tremaine WJ, Hurt RD. Transdermal nicotine for ulcerative colitis. Ann Intern Med. 1997;127:491–3.

    Article  Google Scholar 

  33. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003;17:1355–64.

    Article  CAS  PubMed  Google Scholar 

  34. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, et al. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-ranging trial. Gut. 2006;55:1568–74.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

    Article  CAS  PubMed  Google Scholar 

  36. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Disease Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–96.

    Article  CAS  PubMed  Google Scholar 

  37. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.

    Article  PubMed  Google Scholar 

  38. Sandborn WJ, Feagan BG, Reinisch W, Yan S, Eisenberg D, Bala M, et al. Response and remission are associated with improved quality of life in patients with ulcerative colitis. Gut. 2005;54(Suppl VII):A58.

    Google Scholar 

  39. Lichtenstein G, Kamm M, Sandborn W, Boddu P, Gubergrits N. SPD476 is a novel, once-daily, effective and well-tolerated 5-ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study. Am J Gastroenterol. 2005;100(Suppl):S291.

    Google Scholar 

  40. Kamm M, Sandborn W, Gassull M, Schreiber S, Jackowski L, Mikhailova T. Comparison of the efficacy of SPD476, a novel, once-daily formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: a phase III study. Am J Gastroenterol. 2005;100(Suppl):S291.

    Google Scholar 

  41. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ. 1964;1:89–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission in ulcerative colitis. International study group. Aliment Pharmacol Ther. 1989;3:183–91.

    Article  CAS  PubMed  Google Scholar 

  43. Bewtra M, Brensinger CM, Tomov VT, Hoang TB, Sokach CE, Siegel CA, et al. An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis. 2014;20:1070–8.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Best W, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn’s disease activity index. Gastroenterology. 1976;70:439–44.

    CAS  PubMed  Google Scholar 

  45. Summers RW, Switz DM, Sessions Jr JT, Becktel JM, Best WR, Kern Jr F, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–69.

    CAS  PubMed  Google Scholar 

  46. Singleton JW, Summers RW, Kern Jr F, Becktel JM, Best WR, Hansen RN, et al. A trial of sulfasalazine as adjunctive therapy in Crohn’s disease. Gastroenterology. 1979;77:887–97.

    CAS  PubMed  Google Scholar 

  47. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331:836–41.

    Article  CAS  PubMed  Google Scholar 

  48. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332:292–7.

    Article  CAS  PubMed  Google Scholar 

  49. Willoughby JM, Beckett J, Kum. Controlled trial of azathioprine in Crohn’s disease. N Engl J Med. 1995;332:292–7.

    Article  Google Scholar 

  50. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–35.

    Article  CAS  PubMed  Google Scholar 

  51. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology. 2004;126:1257–69.

    Article  PubMed  Google Scholar 

  52. Frenz MB, Dunckley P, Camporota L, Jewell DP, Travis SP. Comparison between prospective and retrospective evaluation of Crohn’s disease activity index. Am J Gastroenterol. 2005;100:1117–20.

    Article  PubMed  Google Scholar 

  53. Harms HK, Blomer R, Bertele-Harms RM, Shmerling DH, König M, Spaeth A. A pediatric Crohn’s disease activity index (PCDAI). Is it useful? Study Group on Crohn’s Disease in Children and Adolescents. Acta Paediatr Suppl. 1994;83:22–6.

    Article  CAS  PubMed  Google Scholar 

  54. Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, et al. The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37:786–94.

    Article  CAS  PubMed  Google Scholar 

  55. Garrett JW, Drossman DA. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology. 1990;99:90–6.

    Article  CAS  PubMed  Google Scholar 

  56. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Denis MA, Reenaers C, Fontaine F, Belaïche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100–5.

    Article  PubMed  Google Scholar 

  58. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–63.

    Article  PubMed  Google Scholar 

  59. Evertsz FB, Hoeks CC, Nieuwkerk PT, Stokkers PC, Ponsioen CY, Bockting CL, et al. Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn’s disease activity. J Clin Gastroenterol. 2013;47:850–6.

    Article  Google Scholar 

  60. van Hees PA, van Elteren PH, van Lier HJ, van Tongeren JH. An index of inflammatory activity in patients with Crohn’s disease. Gut. 1980;21:279–86.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88–95.

    Article  PubMed  Google Scholar 

  62. Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21:824–31.

    Article  PubMed  Google Scholar 

  63. van der Have M, Fidder HH, Leenders M, Kaptein AA, van der Valk ME, van Bodegraven AA, et al. Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis. 2015;21:369–77.

    Article  PubMed  Google Scholar 

  64. Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn’s disease activity. Aliment Pharmacol Ther. 2015;41:77–86.

    Article  CAS  PubMed  Google Scholar 

  65. Kim ES, Park KS, Cho KB, Kim KO, Jang BI, Kim EY, et al. Development of a Web-based, self-reporting symptom diary for Crohn’s Disease, and its correlation with the Crohn’s Disease Activity Index: Web-based, self-reporting symptom diary for Crohn’s Disease. J Crohns Colitis. 19 Sep 2014. pii:S1873-9946(14)00268-2. doi:10.1016/j.crohns.2014.09.003 [Epub ahead of print].

  66. Surti B, Spiegel B, Ippoliti A, Vasiliauskas EA, Simpson P, Shih DQ, et al. Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale. Dig Dis Sci. 2013;58:1313–21.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, University Hospital CHU of Liège, 4000, Liège, Belgium

    Edouard Louis, Catherine Van Kemseke & Catherine Reenaers

Authors
  1. Edouard Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Van Kemseke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Reenaers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edouard Louis .

Editor information

Editors and Affiliations

  1. Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Charité Medical School—Humboldt-University of Berlin, Berlin, Germany

    Daniel C. Baumgart

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Louis, E., Van Kemseke, C., Reenaers, C. (2017). Objective Assessment of Clinical Disease Activity. In: Baumgart, D. (eds) Crohn's Disease and Ulcerative Colitis. Springer, Cham. https://doi.org/10.1007/978-3-319-33703-6_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33703-6_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33701-2

  • Online ISBN: 978-3-319-33703-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation